All Headlines >>
The maker, MSD Animal Health, says Numelvi is "the first and only “second-generation” Janus kinase (JAK) inhibitor indicated from six months of age (and 3kg) for the treatment of pruritus associated with allergic dermatitis, including atopic dermatitis, as well as the clinical manifestations of atopic dermatitis in dogs. .
It is given once daily and MSD says it is clinically effective after the first dose.
The company says itch relief begins within 2–4 hours and dosing is one tablet a day from day one.
MSD claims Numelvi is at least 10 times more selective for JAK1 compared with other JAK family members (JAK2, JAK3 and TYK2).
Numelvi can be used concurrently with vaccines (including rabies) and other common treatments such as ectoparasiticides, with no requirement for routine blood and urine monitoring.
Dermatology specialist Dr Debbie Gow said: “Second-generation JAK inhibitors are selective — specifically, in this case, more selective for JAK1 than other JAK enzymes.
“The high selectivity for JAK 1 contributes to the favourable safety profile of Numelvi.”
Dr Sue Paterson MA VetMB DVD DipECVD FRCVS added: “Treating canine allergic dermatitis means offering treatment which relieves itch and inflammation, whilst managing any unwanted side effects.
"We want to inhibit JAK 1 to reduce itch and inflammation, whilst having little to no effect on other JAK family members.”
MSD Animal Health will host a lunch-and-learn digital launch event with The Webinar Vet on Thursday 26 March, aiming to set a Guinness World Record for a veterinary educational launch event.
PS: Whilst you're here, take a moment to see our latest job opportunities for vet nurses.